However, a more recent clinical trial demonstrated a reduction in adverse left ventricular remodeling and an improvement in the quality of life in patients diagnosed with severe acute myocardial infarction having received G-CSF treatment after a 10-year follow-up [179]. This evidence concerns the gene CSF3 and acute myocardial infarction.